Cancer-specific mortality (CSM) among patients treated for T1a renal cell carcinoma (RCC) increases along with age across all treatment modalities, according to data presented at the American Urological Association 2020 Virtual Experience.
Using the Surveillance, Epidemiology, and End Results (SEER) database (2004 to 2016), Angela Pecoraro, MD, of AOU San Luigi Gonzaga, University of Turin in Orbassano, Italy, and colleagues identified 44,147 patients with nonmetastatic T1a RCC. The age distribution of these patients were as follows: less than 60 years (19,602, or 44.4%); 60 to 69 years (13,541, or 30.7%), 70 to 79 years (8637, or 19.6%), and 80 years or older (2367, or 5.4%).
Overall, the 5- and 10-year CSM rates rose with increasing age across the 4 treatment modalities examined in the study: partial nephrectomy (PN), radical nephrectomy (RN), local tumor ablation (LTA), and non-interventional management (NIM).
For PN, the 5- and 10-year CSM rates were 0.3% and 1.0%, respectively, for patients younger than 60 years; 0.8% and 3.4% for patients aged 60 to 69 years; 1.8% and 5.7% for those aged 70 to 79 years; and 3.0% and 7.1% for those aged 80 years or older.
For RN, the 5- and 10-year rates were 1.3% and 2.9% for patients younger than 60 years; 2.3% and 5.0% for those aged 60 to 69 years; 3.2% and 7.4% for those aged 70 to 79 years; and 5.7% and 10.2% for patients aged 80 years or older.
Dr Pecoraro’s team observed similar trends among patients treated with LTA. With regard to NIM, they found the association of more advanced age with CSM only among the oldest patients (aged 70 years or older).
The investigators concluded that older T1a RCC patients appear to harbor more aggressive RCC phenotypes than their younger counterparts.
Pecoraro A, Knipper S, Palumbo C, et al. The effect of age on cancer-specific mortality in T1a stage renal cell carcinoma across all treatment modalities: a SEER-based study. Presented at the American Urological Association 2020 Virtual Experience held in May. Abstract MP21-04.